Symprove acquired by Metagenics
Symprove acquired by Metagenics
Transaction
Overview
Spayne Lindsay is delighted to announce that it has advised Metagenics, a leading US-based global nutritional supplement company focused on science-backed, practitioner-recommended products, on its acquisition of Symprove, the UK’s number one probiotic brand.
Symprove is the most recommended probiotic by UK healthcare practitioners and is considered uniquely effective by some of the world’s leading academics. Its clinically proven, water-based formulation addresses digestive illnesses and discomfort and is focused on improving the health of users’ gut microbiomes. The brand is growing rapidly, fueled both by increasing consumer awareness and recommendations from doctors and nutritionists across the world.
Metagenics, backed by Gryphon Investors, delivers high-quality, science-based nutritional supplements, medical foods, and lifestyle programs to support healthcare practitioners as they help patients achieve health and wellness goals. The acquisition of Symprove is highly strategic, enabling Metagenics to grow patient engagement and improve patient results with Symprove’s patented delivery technology through its global practitioner partnership network.
This deal marks another milestone in Spayne Lindsay’s long and successful journey with Symprove, having previously sold the business to bd-capital in 2020, and further strengthens Spayne Lindsay’s extensive credentials in consumer health, adding to a long track record of advising on fast growing, disruptive brands and technologies at the forefront of health and wellbeing.
Our deep industry knowledge, global perspective and strong relationships make us a trusted advisor to leading consumer companies and investors
.png)
.jpg)
.png)
